ROS1 rearrangement defines a second molecular subgroup ofNSCLC for which crizotinib is highly active [7], and crizotinib displays markedantitumor activity in patients with advanced NSCLC with ROS1 rearrangement. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.